Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase II/III trial of Cannabidiol/tetrahydrocannabinol chewing gum (MedChew RX) for the treatment of pain and spasticity in patients with multiple sclerosis

Next Previous
Trial Profile

A phase II/III trial of Cannabidiol/tetrahydrocannabinol chewing gum (MedChew RX) for the treatment of pain and spasticity in patients with multiple sclerosis

Status: Planning
Phase of Trial: Phase II/III

Latest Information Update: 22 Oct 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nabiximols (Primary)
  • Indications Muscle spasticity; Pain
  • Focus Therapeutic Use

    • Most Recent Events

    • 16 Oct 2018 According to an Axim Biotech media release, the company has received a manufacturing license from the Dutch Ministry of Health, Welfare and Sports for the production, according to Good Manufacturing Practices of the companys pharmaceutical products to be used in clinical trials.Under the new GMP license, AXIM will begin production of its flagship pharmaceutical product MedChew Rx, which will undergo this clinical trial.
    • 08 Feb 2016 New trial record
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top